“There has always been a question about whether it is worth using antiepileptic medications to protect against seizures in patients with a brain tumor even though we can’t predict who will actually have a seizure,” said lead review author Ivo Tremont-Lukats, M.D.
Tremont-Lukats is staff neurologist at the Culicchia Neurological Clinic in New Orleans and a clinical assistant professor of neurology at Louisiana State University.
The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.
The review included five studies looking at outcomes in 404 patients with brain tumors but no previous history of seizures. Some received one of three common antiseizure drugs: phenytoin (Dilantin), phenobarbital or divalproex sodium (Depakote). Others patients received a placebo or underwent close observation. Researchers found no differences in preventing the first seizure among the three groups.
“The results are such that we really can’t recommend seizure prevention using these three older anticonvulsants,” Tremont-Lukats said. “There was not a protective effect seen when using these drugs.”
In addition, the risk of side effects — such as drowsiness, bruising and unusual bleeding — was much higher for those using the drugs.
This review looked only at older medications. Because of a lack of usable studies, the researchers could not assess if newer antiepileptic medications might be more useful in stopping first seizures.
“We need to look at the newer generation of anticonvulsants to see if they can protect against first seizures,” Tremont-Lukats said. “These drugs are more specific and have fewer side effects, but we still do not know scientifically if they have a protective effect.”
Tremont-Lukats stressed that this recommendation is only for those who do not have a history of having seizures. If someone has a seizure, then antiepileptic drugs are indicated.
“If a physician wants to put a patient on these medications for more than seven days after surgery, then there may be a problem that the patient should bring up with their doctor,” says Tremont-Lukats. “After a week, there is no evidence that they help and ample evidence of side effects.”
Omkar Markand, M.D., director of the Comprehensive Epilepsy Program at the Indiana University School of Medicine, said that automatically placing people with brain tumors on antiepileptic medications is a common occurrence despite there being no scientific proof that it is useful.
“There is good evidence that all three of the medications have side effects that need to be weighed against any possible benefits,” Markand said. “For those medications, the side effects are worse than any possible benefit. This research is another indication that patients should probably ask their neurosurgeon or other physician if it is really necessary to place them on antiepileptic medication prior to experiencing a seizure.”
Markand stressed that recommendations based on this review are only applicable to the older medications phenytoin, phenobarbital and divalproex sodium.
“The take-home message is that the patients should not accept an automatic placement on antiepileptic medications,” Markand said. “They should ask questions about why these drugs are being prescribed. The needs of the individual should be determined instead of putting everyone on antiepileptic medications.”
Lisa Esposito | EurekAlert!
Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München
Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
22.02.2017 | Power and Electrical Engineering
22.02.2017 | Life Sciences
22.02.2017 | Physics and Astronomy